How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Alicia Castillo Holley hosts Jason Bock on her show. Curative Intent: on Engineering T-Cells, Patient Impact, and Chasing the Impossible. The...

By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC Manufacturing autologous cell therapies requires close coordination with clinical staff, as...

Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems Read the full article...